Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SSBP2 CRISPR/Cas9 KO Plasmid (h): sc-406745
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SSBP2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SSBP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SSBP2 Antibody (D-3): sc-166687
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SSBP2 CRISPR/Cas9 KO Plasmid (h) | sc-406745 | 20 µg | $397.00 |
Overview
SSBP2 (single-stranded DNA binding protein 2) encodes a nuclear DNA-binding factor implicated in genome maintenance and transcriptional control. It participates in cellular programs linked to DNA replication/repair, cell-cycle regulation, and hematopoietic differentiation, and it can influence gene expression through interactions with LIM-domain binding proteins and associated regulatory complexes. Altered SSBP2 expression or disruption has been reported in multiple tumor contexts, consistent with roles in preserving genomic stability and constraining aberrant proliferation. As a consequence, SSBP2 is frequently investigated in studies of oncogenic transformation, stress responses to DNA damage, and lineage-specific transcriptional networks.
SSBP2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SSBP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SSBP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SSBP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SSBP2 protein expression.
This CRISPR knockout system enables efficient generation of SSBP2-deficient cell models for investigation of SSBP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SSBP2 exon(s) critical for SSBP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SSBP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SSBP2 CRISPR/Cas9 KO Plasmid (h) and SSBP2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SSBP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SSBP2 HDR Plasmid (h) and SSBP2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SSBP2 homology arms to support homology-directed repair at defined SSBP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.